Mental Health Claims up 75% Since 2019

FN Media Group Presents Market Commentary


New York, NY – September 23, 2022 –  Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian Life and Health Insurance Association (CLHIA) president and CEO, 2021 was a year of recovery, making mental health support increasingly important. Despite rising demand for mental health care, only 19% of companies in Canada increased their maximum coverage for mental health last year. Luckily, that seems to be changing with several employers beginning to expand their offerings. At the same time, increased awareness surrounding mental wellness is creating an opportunity for companies like Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF), HCA Healthcare (NYSE:HCA), Sage Therapeutics (NASDAQ:SAGE), LifeStance Health Group (NASDAQ:LFST), and Acadia Healthcare (NASDAQ:ACHC) to shine.


Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) is a mental health care company focused on advancing innovative mental health care and safe, evidence-based psychedelic-assisted therapies. Numinus offers a wide range of mental healthcare services, from counseling and therapy to Transcranial Magnetic Stimulation (TMS) to Ketamine-assisted therapy and psychedelic-assisted therapy through Canada’s Special Access Program (SAP).


Numinus has continued to expand its network of clinics and currently operates 13 clinics across Canada and the United States.


On September 22, Numinus announced the opening of a new Montreal location to replace an existing downtown clinic. The new site will have expanded capacity to offer ketamine treatments, including different administrations of ketamine (Spravato, intramuscular, lozenge and nasal spray) and a wider variety of ketamine-assisted therapy options.


Right now, Numinus offers a six-week ketamine-assisted therapy program for the treatment of addiction, depression, anxiety and trauma. The new services will allow patients the option to receive ketamine as a standalone treatment to complement prior ketamine-assisted therapy and can be used as an emergency antidepressant or with therapy from an external health provider.


The company has also expanded its offerings at its Toronto clinic, the Neurology Centre of Toronto (NCT). NCT now offers Ketamine-assisted therapy for individuals with neurologic conditions, including brain injury, epilepsy, concussion, and functional neurological disorders.


NCT includes a team of over 20 specialists offering a comprehensive range of services including primary neurologic care and supportive therapies. The clinic’s new ketamine-assisted therapy service will be led by a psychologist and follow existing protocol for such therapies, which are already being used at the company’s other locations in the US and Canada.


“Following a thorough evaluation, Numinus found NCT’s existing infrastructure, client base and practitioners to be highly suitable for offering ketamine-assisted therapy. Mental health challenges are commonly associated with neurologic diagnoses and ketamine-assisted therapy is a promising tool that we now have available for our patients,” said Dr. Evan Lewis, VP of Psychedelic Neurology at Numinus. “The use of ketamine-assisted therapy within the field of neurology is novel, and we look forward to expanding access for our patients and contributing to the body of knowledge regarding ketamine applications.”


Numinus Wellness also revealed that NCT’s expanded offering will also support applications for Health Canada’s Special Access Programme (SAP) for other psychedelic-assisted therapies. The SAP is a federal program that allows patients with serious or life-threatening conditions to apply for access to investigational medical treatments not yet available to the public, including therapies using psychedelics like MDMA and psilocybin.


Numinus Wellness also provided an update recently on the Novamind acquisition integration in the US. The company’s newly acquired US clinics performed well in fiscal Q4, with a significant increase in customer appointments in recent months. Across August, nearly 6,200 customer appointments were held in Canada and the United States, a 25% increase over July. The company’s eight US wellness clinics – six in Utah and two in Arizona – completed over 4,900 customer appointments in August, a 22% increase over July.


Numinus is working to extend its Ketamine-assisted therapy product across Canada. Ketamine Therapy sessions jumped 35% from July to 1,520 visits in August at Numinus‘ US facilities. The demand for TMS services is also increasing. In August, the company conducted 725 TMS engagements, a 23% increase over the previous month.


For more information about Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF), click here.


Research Continues In the Mental Health Field


HCA Healthcare (NYSE:HCA) announced that it will work with Johnson & Johnson to address critical healthcare industry issues. Improvements in patient outcomes, nursing assistance, and health equity will be the initial focus of the two top healthcare companies. HCA Healthcare continuously enhances treatment using information from more than 35 million patient visits annually. In addition, HCA Healthcare, one of the top employers of Registered Nurses (RNs) in the country with over 93,000 RNs, makes significant investments in nurses and the nursing profession through training and professional development, technology and equipment, and tools to support their physical and emotional wellbeing, and representation at all levels of the business, from the front lines to senior leadership.


Sage Therapeutics (NASDAQ:SAGE) is advancing a clinical program portfolio that includes internally discovered unique chemical entities that have the potential to become differentiated medications that improve brain health by targeting the GABAA and NMDA receptor systems. Many neurological and neuropsychiatric illnesses are thought to be caused by dysfunction in these systems. Sage stated that enrollment in the SUNBIRD Study, which examines the safe use of ZULRESSO as a therapy for PPD in a woman’s home, has concluded. In Q2 2022, net revenue from ZULRESSO sales was $1.5 million, compared to $1.6 million in the same time in 2021.


LifeStance Health Group (NASDAQ:LFST) earned a revenue of $209.5 million in the second quarter, up or 31%, from $160.5 million. Total clinicians increased by 31% to 5,226 in the second quarter, a net gain of 237. Net loss amounted to $68.7 million compared to $70.0 million in the prior-year quarter, principally due to $57.5 million in stock-based compensation expense. Adjusted EBITDA of $14.6 million increased from $14.5 million to $14.6 million. Due to revised clinician seasonality assumptions, LifeStance expects full-year 2022 revenue and Center Margin to be towards the low end of the previously projected ranges of $865 million to $885 million and $240 million to $255 million, respectively. The company reiterated its guidance for adjusted EBITDA of $63 million to $67 million.


On September 14, Acadia Healthcare (NASDAQ:ACHC) reported that a subset of its network of acute care behavioural health institutions will participate in a registration-directed trial to research patients with suicide ideas who are also suffering from severe depression. Seelos Therapeutics is funding this research for its experimental medication SLS-002. Acadia hospitals that meet the criteria for clinical trial site participation will be able to enroll eligible patients who display specified symptoms and meet the enrollment conditions in this study.


Numinus Wellness is actively adding to the body of primary and clinical psychedelic research through its integrated strategy and providing best-in-class therapy regimens across its clinics.


Disclaimer: (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.


The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Numinus Wellness




This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.


Media Contact:

FN Media Group, LLC